FAPI-Based Theranostics in Medullary Thyroid Cancer: A Viable Alternative When Somatostatin Receptor-Based Theranostics Show Limited Efficacy-A Clinical Experience.

We present a case of a 36-year-old man with medullary thyroid carcinoma (MTC) who developed lung metastases 10 years post-total thyroidectomy. He presented with cough, and to evaluate his eligibility for peptide receptor radionuclide therapy (PRRT),…

Preview only. Read the full abstract at the source